u/Lab_Monkey_

u/MGK_2's post earlier today The Convergence... really hit home with me. The idea that all of these innate biological processes that are within everyone of us, and our ancestors for thousands of years, and we are just now beginning to somewhat understand their mechanisms of actions.

What a complex system the human body is. Some say a miracle, others say millions of years of biological trial and error. I for one believe in the biology.

Another byway heading to the Convergence is the little talked about trial SALIENT AD in Alzheimer's led by Dr. Tracy Butler of Weill Cornell Medicine.
The first patient was dosed with 700mg of LL on June 11, 2026, now over 17 weeks ago.
Trial protocol calls for a 12 week treatment period receiving weekly leronlimab doses, then concludes with a 4 week post treatment evaluation phase. 16 weeks.

Thanks to u/AssociationOdd9941 for The Cornell/Donner Connection: Why the Alzheimer’s Trial (SALIENT-AD) is the Ultimate De-Risking Event for Leronlimab

Dr. Jay now has the data from this first patient in hand.
If leronlimab were a city, it would be Rome.
All roads lead to Rome.

https://d1io3yog0oux5.cloudfront.net/cytodyn/sec/0001175680-26-000026/0001175680-26-000026.pdf

"The new drug, taken as two daily pills, attacks a mutated cellular protein called KRAS. It has long been an enticing target, because it fuels nearly all pancreatic cancers, as well as many lung and colon cancers and some other tumor types. But for years, the smooth-surfaced KRAS protein was considered impossible to attack, because it lacked an obvious toehold for a drug to exploit."....

"Dr. Elizabeth Jaffee, a pancreatic cancer researcher at Johns Hopkins, listed some of the most pressing needs in the field: Creating a new generation of KRAS-targeting drugs with fewer side effects; finding ways to overcome the resistance that allows cancer to surge back; and combining KRAS-targeting drugs with other treatments, including those that harness a patient’s immune system to attack cancer."

Sounds very similar to the CLOVER trial.

From the May 5th Update
(Re-read this update if you have any doubts, Cytodyn is very, very busy.)

5/5/2026 CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development

Dr. Jay:

"Equally important on this slide is that the majority of the Clover patients or 62% enrolled to date have KRAS mutations. And these mutations are generally associated with the hardest-to-treat patients in oncology. And these preliminary results indicate that leronlimab's early biologic activity might also be agnostic to the KRAS mutation.

So as you can see some of the slides I showed on the tissue, we are studying the microenvironment to see if it's changing. In parallel, real time, there's a CTC assay from the Creative Microtech from New Jersey that is being done at predefined time points along the way, similar to how it was done in the earlier breast cancer study. So we'll have that data to analyze along the way to see not just the changes in circulating tumor cells, but also the cancer-associated macrophages like cells, the so-called Camel cells. So we'll have a lot of rich data to analyze in the upcoming months to come, as was pointed out earlier.

Importantly, we are targeting the presentation at the ESMO meeting in Madrid, Spain in October to provide an update from the CLOVER study and then a more robust presentation at ASCO GI in San Francisco in January, during which we should be able to provide final results.

And I look forward to updating shareholders later this summer, pending the maturity of those conversations."

GLTAL-monkey

Very informative article. The crux of what leronlimab is all about.

We are on the right path and our trajectory is incoming.

God speed Dr. Jay and crew.  GLTAL   Bring It On Home!